CONNECT2 is PepGen's Phase 2 multinational, double-blind placebo-controlled, multiple ascending dose, 25-week clinical trial of PGN-EDO51 in patients with DMD. The study is open in the United Kingdom.

Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- BOSTON, December 16, 2024--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage ...

Saadia Group, which acquired the department store during a bankruptcy auction four years ago and ran it until early this year, in 2022 had replaced the familiar, idiosyncratic logo with a ...

The motley crew of hypercars and luxury cruisers were driving the Alps near Switzerland, with the crash occurring in the town of Pfunds, Austria, according to Luxury Launches. It's not immediately ...

PGN is both a digital schelling point and the world’s first L2 that works to create durable and recurring funding for public goods. PGN is both a digital schelling point and the world’s first L2 that ...

While the UN Global Compact logo is for use by our initiative only, we encourage participants in good standing to use the Endorser "We Support" logo. It can be used, for example, on websites and ...